Advertisement

Topics

Companies Related to "Combination Chemotherapy Plus Filgrastim in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer" [Most Relevant Company Matches] RSS

00:05 EST 23rd February 2019 | BioPortfolio

Here are the most relevant search results for "Combination Chemotherapy Plus Filgrastim in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer" found in our extensive corporate database of over 50,000 company records.

Showing "Combination Chemotherapy Plus Filgrastim Treating Patients With Previously" Companies 1–25 of 4,300+

Extremely Relevant

NEUPOGEN® (Filgrastim)

NEUPOGEN® (Filgrastim) is Amgen’s first product indicated to decrease the incidence of infection (as manifested by febrile neutropenia)in certain cancer patients who are receiving chemotherapy.


Relevant

Life Time Pharmaceuticals Incorporated

LifeTime™ Pharmaceuticals, a private clinical-stage pharmaceutical company, focuses on the development of drugs that are safe enough for long-term, chronic administration. Compounds currently under development seek to eliminate and prevent recurrence of potentially fatal cancers and infectious syndromes. Human clinical trial results presented at several scientific meetings (see below) have shown...

ProCertus BioPharm, Inc.

ProCertus BioPharm is an oncology-based pharmaceutical company whose primary mission is to protect cancer patients against the side effects of chemotherapy and radiotherapy.ProCertus has established proof of concept in animal models for its product candidates, DermX, ProDermaCel™, and OralX, proprietary pharmaceuticals designed to reduce or eliminate the side effects associated with cancer thera...


Odonate Therapeutics, Inc.

Odonate Therapeutics, Inc. is a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. The Company’s initial focus is on the development of tesetaxel, a novel, orally administered chemotherapy agent belonging to the taxane class. Odonate’s goal for tesetaxel is to ...

Sonrgy, Inc.

Sonrgy is a preclinical stage biotechnology company based in San Diego, California that is developing a targeted chemotherapy delivery platform to improve survival and quality of life for millions of cancer patients. Sonrgy’s tiny nanocarriers safely transport potent chemotherapy drugs to cancer tumors and release high doses on command in response to a focus...

Genetronics Biomedical

Genetronics' most advanced effort involves treating those with head and neck cancer, a particularly devastating cancer that can severely limit the ability of these patients to see, taste, hear, talk, breathe, or swallow. Genetronics received approval from the U.S. Food and Drug Administration and initiated Phase II multi-center clinical trials at nine sites in the U.S. The trials test the effectiv...

DiaTech Oncology

DiaTech Oncology is a privately held clinical pathology laboratory that offers patient-specific chemotherapy testing to help oncologists determine the best cancer treatment plans for their patients. DiaTech utilizes a patented technology called the Microculture Kinetic (MiCK) assay, which measures apoptosis (cell death) induced in a specific patient’s...

Cancer Therapeutics, Inc.TM

Founded in 1991, Cancer Therapeutics, Inc.TM (CTI) is a biotherapy company that is a leader in activated cell technology for cancer therapy. CTI's laboratory offers access to technologies grouped under the modality of Biotherapy. Biotherapy is based on treatments that enhance the patient's own immune system to attack the invading cancer. Research has shown cancer to be a highly individualized dise...

Aranesp

Aranesp® (darbepoetin alfa) is indicated for the treatment of anemia associated with chronic renal failure (CRF), including patients on dialysis and patients not on dialysis, and for the treatment of anemia in patients with nonmyeloid malignancies where anemia is due to the effect of concomitantly administered chemotherapy.Important Product Safety InformationAranesp® is contraindicated in patien...

Targeted Diagnostics and Therapeutics

TDT has emerged as a leader in the development of innovative molecular diagnostics and therapeutics that can improve the quality of life of patients with colorectal cancer and gastrointestinal malignancies. Focused on innovative research and cutting edge technology, TDT has developed highly specific tests to detect colorectal cancer cells in lymph nodes from patients who have undergone surgical st...

GammaCan

GammaCan is a biopharmaceutical company focused on clinical-phase development and commercialization. GammaCan’s initial therapy under development is a first-in-class anti-cancer immunotherapy aimed at preventing metastasis (the spread of cancer to other parts of the body) of a variety of cancers. GammaCan’s first product was entered to phase-II clinical trials.GammaCan’s innovative treatment...

Medivation, Inc.

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation announced a global agreement with Pfizer, Inc to develop an...

Kepivance™ (palifermin)

Kepivance™ (palifermin) is indicated to decrease the incidence and duration of severe oral mucositis (mouth sores) in patients withhematologic (blood) cancers undergoing high-dose chemotherapy, with or without radiation, followed by bone marrow transplant. The safety and efficacy of Kepivance™ have not been established in patients with nonhematologic malignancies.

Lake Champlain Gynecologic Oncology , P.C.

Lake Champlain Gynecologic Oncology is a comprehensive gynecologic oncology center dedicated to the care of women with or suspected of having gynecologic cancers as well as regular gynecologic care for cancer survivors and healthy women. Our office comprises 5500 square feet of easily accessible space with ample on-site parking, 6 exam rooms, a laboratory, a pharmacy, and a chemotherapy infusion c...

Replicon Technologies Incorporated

Replicon Technologies, Inc. (RTI) is an emerging biotechnology company focused on the use of replicons, non-replicating RNA viral particles, for the treatment of patients with cancer. RTI is founded on research and development performed at the University of Alabama at Birmingham (UAB), and supported by competitive grants from the National Institutes of Health, the Department of Defense, and SBIR ...

Intensity Therapeutics, Inc.

Intensity Therapeutics, Inc. is a specialty pharmaceutical company whose mission is to greatly extend the lives of patients with solid tumor cancers. Intensity Therapeutics is pioneering a new approach to treat cancer referred to as in situ chemovaccination. The Company creates novel, proprietary formulations of proven chemotherapy drugs. These products, w...

Targeted Diagnostics & Therapeutics, Inc

TDT has emerged as a leader in the development of innovative molecular diagnostics and therapeutics that can improve the quality of life of patients with colorectal cancer and gastrointestinal malignancies. Focused on innovative research and cutting edge technology, TDT has developed highly specific tests to detect colorectal cancer cells in lymph nodes from patients who have undergone surgical st...

PhotoPharmics

PhotoPharmics is a privately-held, clinical-stage medical device company developing next-generation treatments for treating neurodegenerative disorders through the eyes. Company founders have 30+ years of research and experience in this field. They previously developed specialized light solutions now widely used to regulate circadian rhythms for seasonal a...

Hanmi Pharmaceutical co., Ltd.

Hanmi Pharmaceutical is a Korea-based pharmaceutical company. The Company invests over 20 percent of its sales in R&D and has over 20 programs consisting of the novel long acting biologics including weekly Insulin, weekly to monthly GLP-1, and their combination for diabetes and obesity (collectively referred as Quantum Project), the novel targeted anti-can...

NeuroPace, Inc.

NeuroPace was founded to design, develop, manufacture and market implantable devices for the treatment of neurological disorders by responsive brain stimulation. The company's initial focus is the treatment of epilepsy, a debilitating neurological disorder affecting approximately 1% of the population worldwide. Patients are currently being enrolled in a clinical trial of the company's Responsive N...

Embera NeuroTherapeutics, Inc.

Embera NeuroTherapeutics, Inc. is a development stage pharmaceutical company focused on treating a broad range of addictions and obesity where the major clinical challenge is a limited range of effective drug therapies. Embera is developing a novel drug combination (EMB-001) targeting specific brain functions that drive craving and relapse associated with ...

CerebralRx

Based in Yehud, Israel, CerebralRx was founded in 2010 as a spin-off of BioControl Medical to develop breakthrough implantable neuromodulation systems for the treatment of autonomic nervous system-related neurological disorders. The company’s flagship product is the FitNeS system, an implantable vagus nerve stimulation device for treating patients wit...

GeNO LLC

GeNO LLC, founded in 2006, is a privately held, advanced development-stage technology company that is developing innovative nitric oxide (NO) generation and delivery platforms to enable the true potential of inhaled nitric oxide to be realized. The company is focused on applying the new technology to deliver inhaled nitric oxide to patients in a wide variety of settings, including ambulatory and ...

Neulasta® (pegfilgrastim)

Neulasta® (pegfilgrastim) is approved for once-per-cycle dosing to decrease the incidence of infection (as manifested by febrile neutropenia)in certain cancer patients who are receiving chemotherapy.

Parnell Pharmaceuticals

Parnell Pharmaceuticals is the first company dedicated to the research and development of new and innovative products to restore and maintain mucosal integrity, thereby improving the quality of life of those patients, who for diverse reasons are "mucocompromised", and therefore at increased risk for secondary infections. The majority of these patients are defined as immunocompromised for various r...


More From BioPortfolio on "Combination Chemotherapy Plus Filgrastim in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks